Establishment of a novel Pichia Pastoris host production platform

The Cell Line Development group at Amgen is responsible for manufacturing and optimizing the cell lines utilized in production of Amgen's biologic drug portfolio. Traditionally, these cell lines are produced from mammalian host organisms, primarily Chinese Hamster Ovary (CHO) cells, due to their unique ability to secrete human-like glycosylated proteins. The CHO platform has undergone significant optimization throughout the industry over the past 30 years, however, productivity and efficiency improvements are now becoming harder to realize. Alternative hosts offer a unique opportunity to drive significant cost of goods improvements throughout the biologic drug manufacturing process. Microbial hosts benefit from low genomic complexity, fast doubling times, and can grow to high cell densities in low-cost media. The yeast strain, Pichia pastoris, combines these advantages with the ability to secrete glycosylated products at equivalent product quality levels as CHO-based processes.

Name thesis:degree_name

Master

Department dc:contributor.department

Sloan School of Management

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2020

Author dc:creator

• Coleman, Ellen(Ellen M.)

Advisor dc:contributor.advisor

• J. Christopher Love and Roy Welsch.

• Sloan School of Management.
• Mechanical Engineering.
• Leaders for Global Operations Program.

Statement dc:rights

• MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

https://hdl.handle.net/1721.1/126948

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/126948